Switching to darunavir/ritonavir 800/100mg once-daily containing regimen maintains virological control in fully suppressed pre-treated patients infected with HIV-1

Jade Ghosn*, Laurence Slama, Aziza Chermak, Allal Houssaini, Sidonie Lambert-Niclot, Luminita Schneider, Erwan Fourn, Claudine Duvivier, Anne Simon, Eve Courbon, Robert Murphy, Philippe Flandre, Gilles Peytavin, Christine Katlama, Anne Genevieve Marcelin, Vincent Calvez, Marc Antoine Valantin, Gilles Pialoux, Jean Francois Delfraissy, Serge HersonFrancois Bricaire, Olivier Lortholary, Francois Lecardonnel, Michele Pauchard, Patricia Bourse, Martine Mole, Anne Adda, Fatima Touam, Francoise Pochon, Fabien Sordet, Diane Descamps, France Mentre, Jean Marie Poirie, Caroline Lascoux-Combe

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

14 Scopus citations

Fingerprint

Dive into the research topics of 'Switching to darunavir/ritonavir 800/100mg once-daily containing regimen maintains virological control in fully suppressed pre-treated patients infected with HIV-1'. Together they form a unique fingerprint.

INIS

Pharmacology, Toxicology and Pharmaceutical Science